Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,623Revenue $M297Net Margin (%)-88.8Z-Score1.6
Enterprise Value $M2,749EPS $-3.2Operating Margin %-2.9F-Score4
P/E(ttm))0Cash Flow Per Share $-1.7Pre-tax Margin (%)-90.8Higher ROA y-yN
Price/Book4.910-y EBITDA Growth Rate %0Quick Ratio1.4Cash flow > EarningsY
Price/Sales5.95-y EBITDA Growth Rate %0Current Ratio1.5Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-42.0Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-159.2Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M125ROI % (ttm)-72.1Gross Margin Increase y-yN

Gurus Latest Trades with HZNP

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impact (%)down Price Range
(Average)*
Current Price Change from Average Comment Current Shares
HZNPJoel Greenblatt 2014-12-31 Add$10.61 - $13.47
($12.51)
$ 21.1269%Add 33.48%107,898
HZNPJoel Greenblatt 2014-09-30 Add$8.265 - $16.27
($11.52)
$ 21.1283%Add 39.93%80,834
HZNPJoel Greenblatt 2014-06-30 Buy 0.01$12.02 - $16.32
($14.25)
$ 21.1248%New holding, 57769 sh.57,769
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

HZNP is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
HZNP Joel Greenblatt 2014-12-31107,8980.090.01+33.48%
Premium Most recent portfolio changes are included for Premium Members only!


HZNP: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Himawan JeffDirector 2015-03-13Sell554,564$22.44-6.55view
Himawan JeffDirector 2015-03-10Sell1,614,827$21.85-4.03view
Himawan JeffDirector 2014-11-19Sell3,450,000$12.0574.02view
SHERMAN JEFFREY WEVP and Chief Medical Officer 2014-11-19Sell24,999$12.0574.02view
Walbert Timothy PChairman, President and CEO 2014-11-19Sell150,000$12.0574.02view
Nohria VirinderDirector 2014-11-13Sell2,000,000$11.5481.72view
VENKATARAMAN BALAJIFormer 10% Owner 2014-11-13Sell6,086,957$11.5481.72view
Nohria VirinderDirector 2014-11-13Sell1,739,130$11.5481.72view
Kelly David GeorgeEVP & Corporate Secretary 2014-11-06Sell0$081.72view
DE VAERE ROBERT JEVP & CFO 2014-09-30Sell51,942$12.2870.77view

Press Releases about HZNP :

    Quarterly/Annual Reports about HZNP:

    News about HZNP:

    Articles On GuruFocus.com
    Biotech Effectiveness: Horizon Pharma, Zafgen, XOMA Corp Mar 09 2015 
    Horizon Pharma plc to Host Fourth Quarter 2014 Conference Call and Webcast on February 27, 2015 Jan 28 2015 
    Horizon Pharma plc Provides Business Update Jan 12 2015 
    Horizon Pharma plc Files Patent Infringement Lawsuit Against Watson Laboratories, Inc. for Filing an Dec 24 2014 
    Horizon Pharma plc to Present at the 26th Annual Piper Jaffray Healthcare Conference Nov 24 2014 
    Horizon Pharma plc Announces Pricing of Secondary Offering of Ordinary Shares by Selling Shareholder Nov 14 2014 
    Horizon Pharma plc Announces Proposed Secondary Offering of Ordinary Shares by Selling Shareholders Nov 13 2014 
    Horizon Pharma plc Announces Favorable Markman Ruling in RAYOS(R) (prednisone) Delayed-Release Table Nov 12 2014 
    Horizon Pharma plc Appoints John J. Kody as Executive Vice President and Chief Commercial Officer Nov 06 2014 
    Horizon Pharma plc Announces DUEXIS(R) Selected as Winner of Chicago Innovation Award Oct 31 2014 


    More From Other Websites
    Novo Nordisk's Onset 1 & Onset 2 Meet Primary Objectives - Analyst Blog Mar 26 2015
    Regeneron's Eylea Gets FDA Approval for Label Expansion - Analyst Blog Mar 26 2015
    Momentum bulls stick with Horizon Mar 26 2015
    3 Excellent Biotech Stocks to Buy on the Dip - Stocks in the News Mar 25 2015
    Ignyta Inc, Horizon Pharma PLC: Biotech Hedgie Kevin Kotler Enjoys Strong Gains Mar 25 2015
    Lpath (LPTN) Crumbles on Failure of Kidney Cancer Drug Trial - Analyst Blog Mar 25 2015
    Isis Pharmaceuticals Reports Phase I Data on Lipid Candidate - Analyst Blog Mar 24 2015
    Vertex Falls on Disappointing Kalydeco+VX-661 Combo Data - Analyst Blog Mar 24 2015
    Novo Nordisk's Saxenda Gets EU Approval for Obesity - Analyst Blog Mar 24 2015
    Amicus to Seek for Migalastat's Approval in the U.S., EU - Analyst Blog Mar 20 2015
    Notable option activity in equities Mar 20 2015
    Horizon Pharma and the Chicago Innovation Awards to Ring The Nasdaq Stock Market Closing Bell Mar 20 2015
    Horizon Pharma and the Chicago Innovation Awards to Ring The Nasdaq Stock Market Closing Bell Mar 20 2015
    Lexicon-Ipsen Agreement Expanded to Include Canada - Analyst Blog Mar 19 2015
    Kite Pharma (KITE) Acquires T-Cell Factory, Focus on Europe - Analyst Blog Mar 18 2015
    This Drugmaker Stock Is Attempting A Re-Breakout Mar 18 2015
    HORIZON PHARMA PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale... Mar 16 2015
    Horizon Pharma plc Closes Offering of $400 Million of 2.50% Exchangeable Senior Notes, Including... Mar 13 2015
    HORIZON PHARMA PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a... Mar 13 2015
    Horizon Pharma plc Closes Offering of $400 Million of 2.50% Exchangeable Senior Notes, Including... Mar 13 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK